University of California, Los Angeles Neuro-Oncology : Translational Research : Albert Lai M.D., Ph.D

Contact Us \| Directions \| Referring a Patient
A leading comprehensive brain tumor program, using molecular diagnostic, gene expression analysis, cutting edge clinical trials and advanced medical informatics to customize treatment plans for cancer patients.

Home > Translational Research > Albert Lai M.D., Ph.D

Albert Lai M.D., Ph.D

The Ronald Reagan Hospital at
UCLA Medical Center
710 Westwood Plaza
Reed Bldg RM 1-230
Los Angeles CA 90095

• Assistant Professor in Residence

Attending Physician:
Neurology, UCLA School of Medicine, 2005 - Present

Fellowship:
Neurology, UCLA School of Medicine, 2002 - 2005

Medical Board Certification:
Neurology, American Board of Psychiatry and Neurology, 2004 - Present

Residency:
Neurology, UCLA School of Medicine, 1999 - 2002

Internship:
Internal Medicine, White Memorial Medical Center, 1998 - 1999

Medical Degree:
M.D., UC San Diego School of Medicine, 1998
Ph.D., UC San Diego School of Medicine, 1998

Research Interests

Published Findings


Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys Med Biol. 55(12):3271-85.	Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-72.	Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res PMID: 19934335 ; 69(23):9133-40

Genomic Landscape of Meningiomas. Brain Pathol. PMID: 20015288	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res PMID: 19690143 ; 69(17):6889-98	Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncology PMID: 19655089

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252(1):182-9.PMID: 19561256	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 7;72(14):1217-22.	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics

Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol PMID: 18436627	Time course of imaging changes of GBM during extended bevacizumab treatment J Neurooncol. PMID: 18389177	Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. Int J Radiat Oncol Biol Phys PMID: 18355978

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. PMID: 18215105	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol PMID: 17947718	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 Clin Cancer Res PMID: 17473188 (9):2592-8.	MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258-60. PMID: 16636248

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.

Portions Copyright (Search, Chart, Content Publishing Tools, Photography, Provider^IQ) 1998-2010 SiliconMED North America

Provider^IQ is a registered trademark of SiliconMED North America and used by permission.

[Content Published:9/4/2010 10:38:16 AM PST]